ChemoCentryx Will Regain Global Rights for Vercirnon from Glaxo, Will Assess If Drug Maintains Remission in Crohn's Disease

ChemoCentryx, Inc. (Nasdaq: CCXI ) announced that GlaxoSmithKline (NYSE: GSK ) has returned to ChemoCentryx all rights to vercirnon (also known as Traficet-EN and CCX282), an inhibitor of the chemokine receptor known as CCR9, for all indications, including the treatment of inflammatory bowel disease. "We are pleased to have a response from GSK